Ignite Creation Date:
2025-12-24 @ 6:42 PM
Ignite Modification Date:
2025-12-29 @ 8:25 PM
Study NCT ID:
NCT05530057
Status:
RECRUITING
Last Update Posted:
2025-11-20
First Post:
2022-09-01
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer
Sponsor:
Seoul National University Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-02-18
Start Date Type:
ACTUAL
Primary Completion Date:
2028-06-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-06-30
Completion Date Type:
ESTIMATED
First Submit Date:
2022-09-01
First Submit QC Date:
None
Study First Post Date:
2022-09-07
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-17
Last Update Post Date:
2025-11-20
Last Update Post Date Type:
ESTIMATED